Actinium Pharmaceuticals has reported data from the Phase III SIERRA clinical trial of Iomab-B (Iodine-131-apamistamab) to treat patients with relapsed or refractory acute myeloid leukaemia (r/r AML).
The randomised, multicentre, controlled trial enrolled 153 people aged 55 years and above with r/r AML and those who were heavily pre-treated and had high-risk characteristics such as a TP53 mutation.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It compared the outcomes of those receiving Iomab-B and a bone marrow transplant (BMT) to those who received a physician’s choice of salvage chemotherapy and standard allogeneic BMT in the control arm.
According to the findings, the trial met its primary endpoint of durable complete remission (dCR) and showed a significant improvement in event-free survival (EFS).
The trial achieved a 22% dCR rate in the Iomab-B arm compared to 0% in the control arm.
This result was statistically significant and highlighted the potential of Iomab-B in inducing remission in patients with r/r AML.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHowever, the SIERRA trial did not meet the secondary endpoint of overall survival (OS) on an intent-to-treat basis analysis. This was attributed to the high crossover rate, with nearly 60% of control arm patients eventually receiving Iomab-B followed by a BMT.
Supplemental analyses of the SIERRA trial data indicated improved survival outcomes, particularly in patients with a TP53 mutation and increased one- and two-year overall survival rates in patients aged 65 years and above.
Actinium chairman and CEO Sandesh Seth said: “We believe the SIERRA trial was a major advancement for the field of BMT and targeted radiotherapeutics but most importantly for patients with r/r AML.
“We look forward to completing our interactions with the FDA to finalise the specifics of the additional Phase III randomised trial and working to secure a US partner for Iomab-B. In doing so, we hope to accelerate Iomab-B reaching patients with high unmet need that can benefit from a bone marrow transplant.”
